{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:11:49Z","timestamp":1786119109949,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1097\/ijg.0b013e3181666557","type":"journal-article","created":{"date-parts":[[2008,12,17]],"date-time":"2008-12-17T03:30:08Z","timestamp":1229484608000},"page":"667-673","source":"Crossref","is-referenced-by-count":96,"title":["Efficacy and Tolerability of Prostaglandin Analogs"],"prefix":"10.1097","volume":"17","author":[{"given":"Florent","family":"Aptel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Cucherat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210208","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff","year":"2004","journal-title":"Bull World Health Organ"},{"key":"R2-11-20210208","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0025-6196(11)63007-3","article-title":"Glaucoma: changing concepts and future directions","volume":"71","author":"Liesegang","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"R3-11-20210208","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R4-11-20210208","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R5-11-20210208","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/00002512-199914050-00006","article-title":"Prostaglandin analogues in the treatment of glaucoma","volume":"14","author":"Linden","year":"1999","journal-title":"Drugs Aging"},{"key":"R6-11-20210208","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0161-6420(01)00584-X","article-title":"Bimatoprost Study Group. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial","volume":"108","author":"Brandt","year":"2001","journal-title":"Ophthalmology"},{"key":"R7-11-20210208","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0161-6420(96)30750-1","article-title":"A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group","volume":"103","author":"Watson","year":"1996","journal-title":"Ophthalmology"},{"key":"R8-11-20210208","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0161-6420(02)01010-2","article-title":"Travoprost Study Group. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial","volume":"109","author":"Fellman","year":"2002","journal-title":"Ophthalmology"},{"key":"R9-11-20210208","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","article-title":"XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study","volume":"135","author":"Parrish","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R10-11-20210208","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","article-title":"Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials","volume":"112","author":"Van der Valk","year":"2005","journal-title":"Ophthalmology"},{"key":"R11-11-20210208","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0197-2456(89)90067-6","article-title":"Considerations for the meta-analysis of randomized clinical trials. Summary of a panel discussion","volume":"10","author":"Boissel","year":"1989","journal-title":"Controlled Clin Trials"},{"key":"R12-11-20210208","article-title":"La M\u00e9ta-analyse des Essais Th\u00e9rapeutiques","author":"Cucherat","year":"1997"},{"key":"R13-11-20210208","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"For the QUOROM Group Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"R14-11-20210208","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/bmj.38446.498542.8F","article-title":"Optimal search strategies for retrieving scientifically strong studies of treatment from medline: analytical survey","volume":"330","author":"Haynes","year":"2005","journal-title":"Br Med J"},{"key":"R15-11-20210208","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1185\/030079905X65600","article-title":"Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma","volume":"21","author":"Holmstrom","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R16-11-20210208","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2004.02.017","article-title":"Advanced Glaucoma Intervention Study. Predictive factors for glaucomatous visual field progression in the advanced glaucoma intervention study","volume":"111","author":"Nouri-Mahdavi","year":"2004","journal-title":"Ophthalmology"},{"key":"R17-11-20210208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R18-11-20210208","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.288.19.2406-JLT1120-4-1","article-title":"Allocation concealment in clinical trials","volume":"288","author":"Schulz","year":"2002","journal-title":"JAMA"},{"key":"R19-11-20210208","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.288.19.2407-JLT1120-4-2","article-title":"Allocation concealment in clinical trials","volume":"288","author":"Juni","year":"2002","journal-title":"JAMA"},{"key":"R20-11-20210208","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"R21-11-20210208","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0895-4356(94)00136-E","article-title":"Statistical and theoretical considerations in meta-analysis","volume":"48","author":"Olkin","year":"1995","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"R22-11-20210208","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.1016\/S0039-6257(01)00212-0","article-title":"Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost","volume":"45","author":"DuBiner","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"R23-11-20210208","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(02)01827-5","article-title":"A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma","volume":"135","author":"Noecker","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"R24-11-20210208","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.survophthal.2003.12.017","article-title":"24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial","volume":"49","author":"Walters","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"R25-11-20210208","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF02850299","article-title":"Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension","volume":"18","author":"Gandolfi","year":"2001","journal-title":"Adv Ther"},{"key":"R26-11-20210208","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1136\/bjo.2006.094326","article-title":"Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension","volume":"90","author":"Cantor","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"R27-11-20210208","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.survophthal.2003.12.015","article-title":"Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension","volume":"49","author":"Cantor","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"R28-11-20210208","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","article-title":"Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension","volume":"132","author":"Netland","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R29-11-20210208","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/sim.1207","article-title":"Meta-analysis combining parallel and cross-over clinical trials. III: the issue of carry-over","volume":"21","author":"Curtin","year":"2002","journal-title":"Stat Med"},{"key":"R30-11-20210208","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ophtha.2005.10.045","article-title":"Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension","volume":"113","author":"Orzalesi","year":"2006","journal-title":"Ophthalmology"},{"key":"R31-11-20210208","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ophtha.2004.08.022","article-title":"Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients","volume":"112","author":"Konstas","year":"2005","journal-title":"Ophthalmology"},{"key":"R32-11-20210208","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1442-9071.2006.01237.x","article-title":"Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials","volume":"34","author":"Li","year":"2006","journal-title":"Clin Exp Ophthalmol"}],"container-title":["Journal of Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IJG.0b013e3181666557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:27:21Z","timestamp":1786037241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00061198-200812000-00011"}},"subtitle":["A Meta-analysis of Randomized Controlled Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ijg.0b013e3181666557","relation":{},"ISSN":["1057-0829"],"issn-type":[{"value":"1057-0829","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}